Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era
Apr 21, 2026 - 01:10:08
Radio and PodcastLive Radio & PodcastsKate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
Ep192: Kate Haviland on Following the Science to Precision Immunology is an episode from The Long Run with Luke Timmerman by The Long Run with Luke Timmerman. Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned...
This episode belongs to The Long Run with Luke Timmerman.
Use the player on this page to stream the episode online.
Published Jan 8, 2026, 01:26:06 long, audio available.
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
You can listen to Ep192: Kate Haviland on Following the Science to Precision Immunology online on Radio and Podcast. Open the player on this page to stream the available audio.
Ep192: Kate Haviland on Following the Science to Precision Immunology is an episode from The Long Run with Luke Timmerman by The Long Run with Luke Timmerman.
This episode is 01:26:06 long.
This episode was published on Jan 8, 2026.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from The Long Run with Luke Timmerman when more episodes are available from the podcast feed.
You can listen to Ep192: Kate Haviland on Following the Science to Precision Immunology on this page when the episode audio is available from the podcast feed.
Ep192: Kate Haviland on Following the Science to Precision Immunology is from The Long Run with Luke Timmerman by The Long Run with Luke Timmerman.
Published Jan 8, 2026 and 01:26:06 long